Effect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion
Abstract Objective Insulin secretion is regulated by ATP-sensitive potassium (KATP) channels in pancreatic beta-cells. Peroxisome proliferator-activated receptors (PPAR) α ligands are clinically used to treat dyslipidemia. A PPARα ligand, fenofibrate, and PPARγ ligands troglitazone and 15-deoxy-∆12,...
Main Authors: | Shigeki Kitamura, Naoya Murao, Shoko Yokota, Masaru Shimizu, Tomoyuki Ono, Yusuke Seino, Atsushi Suzuki, Yuko Maejima, Kenju Shimomura |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | BMC Research Notes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13104-023-06489-7 |
Similar Items
-
Efficacy of Pemafibrate in Comparison to Fenofibrate and Bezafibrate on Triglyceride Levels and Liver, and Renal Functions in Patients With Hypertriglyceridemia and Type 2 Diabetes
by: Junko Oya, et al.
Published: (2023-11-01) -
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
by: Akihiro Honda, et al.
Published: (2022-04-01) -
Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis
by: Kazufumi Dohmen, et al.
Published: (2021-10-01) -
Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
by: Zhe Zhang, et al.
Published: (2022-07-01) -
Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis
by: Shizuya Yamashita, et al.
Published: (2023-05-01)